www.jdsupra.com ·
wound care and skin substitute 3945082
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedRegulatory crackdown on wound care and skin substitutes in the US, driven by fraud investigations and a 90% cut in Medicare reimbursement, directly impacts revenue and margins for manufacturers and providers of skin substitutes. The channel is regulatory (reimbursement cut) and compliance cost. Winners: none; losers: skin substitute manufacturers (e.g., Misonix, Organogenesis) and wound care providers. Impact is US-specific.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Medicare spending on skin substitutes could rise from $400 million in 2022 to over $10 billion in 2024 due to overutilization.
- Changes to the Medicare Physician Fee Schedule have reduced payments for skin substitutes by nearly 90%.
- UPIC Notices of Overpayment have been issued, with some overpayments exceeding $800,000.
- A Local Coverage Determination for skin substitutes was withdrawn before its January 1, 2026 effective date.
- Regulatory scrutiny from DOJ, HHS-OIG, and CMS has intensified over the past 18 months.
Over 1-4 weeks, skin substitute market contracts further as providers exit and consolidation accelerates, leading to a 40-60% revenue drop.
Sign in to see all sector verdicts, full thesis and counter-argument debate.